Roche boasts new Lucentis approval for retinal damage in diabetes

Carly Helfand
now has another under its belt for eye drug . And it’s in a market it can call its own: is the first U.S.-approved treatment for diabetic retinopathy in patients with diabetic macular edema.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS